Cancer Multiple Myeloma

Table of Contents

RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Multiple Myeloma Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects

--Top Companies in late stage Multiple Myeloma Projects
--Attenuon, L.L.C.
--Amgen Inc
--Centocor, Inc.
--Celgene Corporation
--CuraGen Corp
--Cephalon Inc
--Genentech Inc
--Enzon Pharmaceuticals Inc
--Gloucester Pharmaceuticals
--Genmab A/S
--Human Genome Sciences Inc
--Heidelberg Pharma AG
--Incyte Corporation
--Immunomedics Inc
--Johnson & Johnson
--Italfarmaco S.p.A
--NatImmune A/S
--Millennium Pharmaceuticals Inc
--Topotarget A/S
--PharmaMar

--Top Companies in early stage Multiple Myeloma Projects
--AERES Biomedical Ltd.
--Abiogen Pharma S.p.A.
--Cephalon Inc
--Alexion Pharmaceuticals Inc
--CYTOGEN Corporation
--Chugai Pharma USA, LLC.
--Genentech Inc
--Gemin X Biotechnologies Inc.
--ImmunoGen Inc
--GLYCOTOPE GmbH
--Innate Pharma S.A.
--Immunomedics Inc
--Merck & Co Inc
--Kyowa Hakko Kogyo Co., Ltd.
--Nereus Pharmaceuticals, Inc.
--MorphoSys AG
--Novartis AG
--Nicholas Piramal India Limited
--Semafore Pharmaceuticals
--erly ComChem Technologies)
--Onyvax Limited

Pipeline Revenue
--Pipeline Revenue
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Pending Approval Pipeline View
--Post Marketing Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View